Le PASI absolu et sa corrélation avec le DLQI : analyse post hoc de l’étude CLEAR

M. Reinhardt(Novartis (Germany)), Karin Reich(Dermatologikum Hamburg), Nils Melzer(Novartis (France)), Andreas Pinter(Goethe University Frankfurt), P. Celérier(Centre Hospitalier de La Rochelle), J.‐P. Lacour(Centre Hospitalier Universitaire de Nice), M. Ruer‐Mulard, Diamant Thaçi(University of Lübeck), Lucie Martin(Novartis (France)), M. Beylot‐Barry(Université de Bordeaux)
Annales de Dermatologie et de Vénéréologie
November 25, 2017
10.1016/j.annder.2017.09.431
Cited by 0

Related Papers

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Inefficacy of Immediate Node Dissection in Stage 1 Melanoma of the Limbs
|New England Journal of Medicine|1977|667
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
|British Journal of Dermatology|2020|590
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580